A review of latest clinical practice guidelines for the management of cancer-associated thrombosis
Authors:
- 27 May 2022
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 35 (1) , 101348
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFYBMC Cancer, 2011
- AGREE II: Advancing guideline development, reporting and evaluation in health careJournal of Clinical Epidemiology, 2010
- Prevention of Venous Thromboembolism in Hospitalized Patients With CancerJournal of Clinical Oncology, 2009
- Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patientsJournal of Thrombosis and Haemostasis, 2009
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Venous Thromboembolism in the Outpatient SettingArchives of internal medicine (1960), 2007
- A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer SurgeryAnnals of Surgery, 2006
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood, 2002
- A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsNew England Journal of Medicine, 1999